Descrizione del progetto
Un approccio rigenerativo mirato per il trattamento dell’incontinenza
L’incontinenza fecale è l’incapacità di controllare i movimenti intestinali, il che causa la perdita di feci. Il progetto AMELIE, finanziato dall’UE, è composto da un consorzio di esperti altamente interdisciplinare che propongono un nuovo intervento rigenerativo utilizzando cellule autologhe di derivazione muscolo-scheletrica per ripristinare la funzionalità del muscolo sfinterico. Gli scienziati faranno aderire tali cellule autologhe ai microsupporti impiantabili, per migliorare la somministrazione e l’attecchimento delle cellule nei pazienti con incontinenza fecale e il procedimento sarà testato in una sperimentazione clinica randomizzata. Si prevede che la strategia possa migliorare la vitalità delle cellule e aumentare le probabilità di rigenerazione muscolare, contribuendo al miglioramento dell’incontinenza.
Obiettivo
Faecal incontinence (FI) is a common condition affecting ~67 million people in Europe, seriously impairing living and productivity of affected individuals and their families. Women with FI arising from childbirth injury may benefit from regenerative medicine using autologous skeletal muscle derived cells (ASMDC) to restore function of damaged sphincter muscle. However, progress is hindered by sub-optimal manufacturing and delivery techniques contributing to inconsistent results. AMELIE proposes an innovative approach that uses ASMDC attached to implantable microcarriers that will enable delivery of a higher number of viable ASMDC into the damaged sphincter muscle, increasing the likelihood of cell engraftment, regeneration of muscle and improved continence. To achieve this, AMELIE will develop bespoke implantable microcarriers suitable for clinical use; establish robust bioprocessing for manufacture of the cell-microcarrier combination; and for the first time, robustly test, in a randomised clinical trial, the principle that delivery of ASMDC in an anchored, natural state, provides more effective and consistent treatment. AMELIE comprises a highly interdisciplinary, gender balanced, consortium of internationally recognised experts and key-opinion leaders with relevant experience from academia and industry across Europe in the fields of engineering (IST, PS, UCL, NHSBT), biological sciences (NHSBT, UCL, IISFJD), and translational regenerative medicine (QMUL, MUG, AUH, AU, RUH, UHE, IISFJD, CVBF). BCR will lead dissemination activity and stakeholder interaction with patients and the public, healthcare professionals, industry and third party FI charities across Europe to establish reciprocal dialogue with people that will interact with the new technology throughout the lifetime of the AMELIE project. TTOP will lead knowledge management and exploitation to develop a marketing strategy and business plan to facilitate future exploitation of the technology to ensure patient benefit.
Campo scientifico
Parole chiave
Programma(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SC1-2019-Single-Stage-RTD
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
WC1E 6BT London
Regno Unito